HRT vs Antidepressants for Vasomotor Symptoms: Which Works Better?

How Effective Is HRT Compared to Antidepressants for Hot Flashes?

HRT is substantially more effective than antidepressants for vasomotor symptoms. The NAMS 2023 Position Statement states that "hormone therapy remains the most effective treatment for vasomotor symptoms of menopause," with clinical trials consistently showing 75 to 90 percent reductions in hot flash frequency and severity. Antidepressants produce meaningful but smaller benefits, roughly 50 to 60 percent reductions, in women who cannot use estrogen.

The Menopause Hormone Therapy (MHT) trials that underpinned U.S. prescribing patterns used conjugated equine estrogen (CEE) or estradiol at doses ranging from 0.3 mg to 1.25 mg orally or 0.025 mg to 0.1 mg transdermally. A 2004 Cochrane review of 24 randomized controlled trials found that estrogen reduced the number of hot flashes per day by a weighted mean of 2.32 events compared to placebo, and reduced composite flush scores by 87 percent in some arms. [1]

For antidepressants, the evidence base is narrower. A meta-analysis published in the Journal of General Internal Medicine (2006, N=2,000 participants across 10 trials) found that SSRIs and SNRIs reduced vasomotor symptom frequency by about 54 percent versus 26 percent for placebo. [2] Venlafaxine 75 mg daily and paroxetine 7.5 mg (Brisdelle) have the largest trial datasets. Paroxetine 7.5 mg (Brisdelle) is the only SSRI/SNRI with an FDA indication specifically for vasomotor symptoms. [3]

Fezolinetant (Veozah), a neurokinin B receptor antagonist approved by the FDA in May 2023, offers a third category entirely. It is neither a hormone nor an antidepressant, yet in the SKYLIGHT 1 and SKYLIGHT 2 trials (combined N=1,022), it reduced moderate-to-severe hot flash frequency by 60 percent at week 12 compared to 45 percent for placebo. [4]

What Does "Bioidentical" Actually Mean, and Does It Matter?

"Bioidentical" means the hormone molecule is structurally identical to the one the human ovary produces. It says nothing about whether the product is FDA-regulated. That distinction matters clinically.

FDA-approved bioidentical estradiol products include Vivelle-Dot (patch), Climara (patch), Divigel (gel), EstroGel (gel), and Evamist (spray). All contain 17-beta estradiol, the same molecule produced endogenously. Micronized progesterone (Prometrium) is the FDA-approved bioidentical progestogen. These products have standardized dosing, stability testing, and manufacturing oversight under 21 CFR Part 211.

Compounded bioidentical hormone therapy (cBHT) is mixed by a pharmacy to a prescriber's specification. The FDA has not approved compounded HRT, and the agency's 2020 advisory cautioned that "compounded drugs are not FDA-approved and have not been demonstrated to be safe and effective." [5] The Endocrine Society's 2016 Scientific Statement concluded that cBHT lacks evidence of superior efficacy or safety compared to FDA-approved products, and raises concerns about dosing accuracy, contamination, and inconsistent potency. [6]

A practical decision framework for choosing between compounded and FDA-approved HRT:

1. Standard doses available as FDA-approved products. Use the approved product. Regulatory oversight is real, and potency is verified.
2. Allergy to a specific inactive ingredient in every approved formulation. Compounding may be clinically justified, with documentation.
3. Dose not commercially available (e.g., very low estradiol for women with dose-limiting side effects). Compounding is a reasonable fallback, with explicit informed consent about the regulatory status.
4. Patient preference for "natural" or "custom" without a medical indication. Counsel on the lack of comparative safety data before prescribing.

Synthetic estrogens such as conjugated equine estrogen (Premarin) and ethinyl estradiol are not bioidentical. CEE remains a well-studied option with decades of safety data from the Women's Health Initiative (WHI), but it is not the same molecule as endogenous estradiol and metabolizes differently.

Oral vs Transdermal Estradiol: Which Carries Less Risk?

Transdermal estradiol carries a lower risk of venous thromboembolism (VTE) and stroke than oral estradiol at equivalent therapeutic doses. This is not a minor difference in high-risk women.

Oral estradiol undergoes hepatic first-pass metabolism, triggering increased synthesis of coagulation factors, C-reactive protein, sex hormone-binding globulin, and triglycerides. A large French observational study (the ESTHER study, N=881 cases, published in Circulation 2007) found that oral estrogen users had a 4-fold increase in VTE risk, while transdermal estrogen users had no statistically significant elevation compared to non-users (adjusted odds ratio 0.9 to 95% CI 0.4-2.1). [7]

A nested case-control study using the UK General Practice Research Database (N=15,710 women) published in the BMJ in 2010 confirmed that transdermal estradiol did not raise VTE risk (odds ratio 0.81 to 95% CI 0.62-1.07), while oral formulations did (odds ratio 1.49 to 95% CI 1.22-1.82). [8]

For most healthy women under 60 who begin HRT within 10 years of their final menstrual period, this difference is small in absolute terms. For women with obesity (BMI >30), a personal or family history of VTE, or thrombophilia, the transdermal route is the clinically preferred choice.

Patch vs Gel Estradiol: Practical Differences

Both the patch and the gel deliver estradiol transdermally, bypassing hepatic first-pass metabolism, and both are FDA-approved and bioidentical. The clinical outcomes are equivalent at matched serum estradiol levels. The choice comes down to application preference, skin tolerability, and adherence.

Patches such as Vivelle-Dot (0.025 to 0.1 mg per 24 hours) are changed twice weekly (or once weekly for the Climara formulation). They deliver steady-state estradiol levels quickly, typically within 24 to 48 hours. Skin irritation or adhesion failure in hot or humid conditions affects roughly 10 to 20 percent of patch users, based on prescribing information data. [9]

Gels such as Divigel (0.1% estradiol) and EstroGel (0.06% estradiol pump) are applied once daily to the thigh or upper arm. They allow flexible dose titration in smaller increments. A pooled analysis of Divigel trials (N=495) showed that 0.1 g and 0.25 g daily doses both significantly reduced moderate-to-severe vasomotor symptoms versus placebo (P<0.001) at 12 weeks. [10] Transfer to a partner or child through skin contact is a documented risk with gels; the FDA requires label warnings on all topical estrogen products. [11]

For women with sensitive skin, the gel avoids adhesive contact dermatitis. For women who want a set-and-forget approach, twice-weekly patches may improve adherence. Neither formulation has a clinically demonstrated VTE risk advantage over the other.

When Are SSRIs and SNRIs the Right Choice?

Antidepressants for vasomotor symptoms are a reasonable first-line option in four specific situations: active or recent hormone-receptor positive breast cancer, a personal history of VTE or stroke, severe hypertriglyceridemia worsened by oral estrogen, and patient preference after fully informed counseling.

Paroxetine 7.5 mg (Brisdelle) is the only SSRI with FDA approval for vasomotor symptoms, distinct from its higher antidepressant doses. In the two key Phase 3 trials supporting approval (combined N=1,175), it reduced mean daily hot flash frequency by 33 percent more than placebo at week 4, with the separation persisting at week 24. [3] Side effects at this dose include nausea (9.7%), dizziness (4.5%), and fatigue (3.1%).

Venlafaxine 37.5 to 75 mg daily (an SNRI) is widely used off-label and has a strong evidence base. A randomized trial by Loprinzi et al. published in The Lancet (2000, N=191) found that venlafaxine 75 mg reduced hot flash scores by 61 percent at 4 weeks versus 27 percent for placebo. [12] An important drug interaction: paroxetine is a potent CYP2D6 inhibitor and reduces tamoxifen conversion to its active metabolite endoxifen by up to 64 percent. Women on tamoxifen for breast cancer should avoid paroxetine and prefer venlafaxine or desvenlafaxine instead. [13]

Gabapentin 300 mg three times daily is a non-antidepressant, non-hormonal alternative with moderate evidence. A randomized trial (N=59) published in Obstetrics and Gynecology (2003) found 45 percent hot flash reduction versus 29 percent for placebo. [14] It is not FDA-approved for vasomotor symptoms but is commonly used off-label.

"The Menopause Society recommends that hormone therapy be used as first-line management of vasomotor symptoms of menopause in the absence of contraindications, and that non-hormonal options including SSRIs, SNRIs, and gabapentin are appropriate alternatives," per the NAMS 2023 Position Statement. [15]

How to Choose: A Clinical Decision Map

The choice between HRT and antidepressants for vasomotor symptoms should follow a structured risk-benefit assessment. Age, time since menopause, uterine status, cardiovascular risk, breast cancer history, and symptom severity all factor in.

The "timing hypothesis," supported by WHI re-analyses by Manson et al. (JAMA 2013, N=27,347 WHI participants), holds that women who start HRT within 10 years of menopause or before age 60 see net cardiovascular benefit, while women starting more than 10 years after menopause may face increased coronary risk. [16] This is the clinical basis for the NAMS guideline that HRT is appropriate for most symptomatic women under 60 without contraindications.

For women with a uterus, systemic estrogen must be paired with a progestogen to prevent endometrial hyperplasia. Options include micronized progesterone (Prometrium 100 to 200 mg daily), norethindrone acetate, or a progestogen-releasing IUD (levonorgestrel 52 mg, such as Mirena). The PEPI trial (N=875, JAMA 1995) showed that unopposed estrogen increased endometrial hyperplasia risk to 62 percent over 3 years versus 1 percent with estrogen plus progesterone. [17]

Women with severe or frequent vasomotor symptoms (7 or more moderate-to-severe events per day) are the most likely to achieve clinically meaningful relief only with estradiol. The number needed to treat (NNT) to achieve 50 percent or greater hot flash reduction is approximately 3 for estradiol versus 7 for SSRIs/SNRIs, based on pooled trial data. [1, 2]

Oral vs Transdermal in Younger Postmenopausal Women

For women under 55 with no cardiovascular risk factors, oral estradiol 1 mg daily or oral CEE 0.625 mg daily are effective and well-tolerated starting points. Oral estrogen raises HDL cholesterol, which may offer some cardiovascular benefit in this younger age group, an effect attenuated or absent with transdermal delivery. A sub-study of the Kronos Early Estrogen Prevention Study (KEEPS, N=727) published in Menopause (2014) found that oral CEE raised HDL by 5 mg/dL versus no significant change with transdermal estradiol. [18]

The clinical implication is narrow. For women under 55 without VTE risk factors, the oral route remains appropriate. For women 55 to 65, particularly those with obesity, migraines with aura, or a family history of clot, the transdermal route is the better default.

The dose titration schedule matters too. Starting low (0.025 mg patch or 0.25 g Divigel daily) and reassessing at 8 to 12 weeks avoids over-treating women whose symptoms resolve quickly and allows dose escalation for non-responders before switching formulations.

Safety Overview: What the Numbers Actually Show

The Women's Health Initiative (WHI) results published in JAMA 2002 (N=16,608 for the CEE plus medroxyprogesterone arm) reported a hazard ratio of 1.26 for invasive breast cancer, 1.29 for coronary heart disease, and 2.11 for pulmonary embolism with combined CEE plus MPA versus placebo over 5.2 years. [19] These figures alarmed many clinicians and drove a sharp drop in HRT prescribing.

Context is everything. The WHI enrolled women with a mean age of 63, more than 12 years past menopause on average. The findings have limited applicability to women aged 50 to 55 starting HRT for symptom control. The estrogen-only arm (women without a uterus, N=10,739) showed no statistically significant increase in breast cancer risk (HR 0.77 to 95% CI 0.59-1.01) after 7.1 years. [20]

For antidepressants, the main safety concerns at vasomotor-symptom doses are sexual dysfunction, discontinuation syndrome on stopping paroxetine, hyponatremia in elderly women on SSRIs, and the tamoxifen interaction noted above. Fezolinetant carries a label warning about hepatotoxicity; liver enzymes should be checked before initiation and periodically thereafter. [4]

A 2023 review in the New England Journal of Medicine concluded that "for women younger than 60 years or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for treatment of vasomotor symptoms," reinforcing the timing hypothesis with updated observational and trial data. [21]